Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense RNA coronavirus responsible for the COVID-19 pandemic. Since December 2019, coronavirus disease 2019 (COVID-19) has affected more than 127 million people, 2.7 million deaths globally (as per WHO dashboard, dated 31 March, 2020), the virus is capable of transmitting from human to human via inhalation of infected respiratory droplets or aerosols or contact with infected fomites. Clinically, patients with COVID-19 present with severe respiratory distress syndrome, which is very similar to the presentation of other respiratory viral infections. A huge variation in the host response exists, with the resulting symptoms varying from mild to moderate. Comorbidities such as cardiovascular disease, hypertension, diabetes, coagulation dysfunction, stroke, malignant tumor and multiple organ dysfunction syndrome, as well as age and sex, are associated with severe COVID-19 cases. So far, no targeted therapies have been developed to treat this disease and existing drugs are being investigated for repurposing. This chapter discusses the epidemiology, clinical features of COVID-19, pathogenesis and the innate and adaptive immune response mounted by the host to the SARS-CoV-2 infection. A deeper understanding of the host-pathogen interaction is fundamental to the development of a vaccine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aftab SO, Ghouri MZ, Masood MU et al (2020) Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med 18:275. https://doi.org/10.1186/s12967-020-02439-0
Alsaadi E, Jones I (2019) Membrane binding proteins of corona viruses. Futur Virol 14(4):275–286
Andrei G, De Clercq E (1993) Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res 22:45–75. https://www.roche.com/media/releases/med-cor-2020-03-19.htm~
Backer JA, Klinkenberg D, Wallinga J (2020) Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Eurosurveillance. 25:2000062
Balakrishnan VS (2020) The arrival of Sputnik V-Controversy continues to brew around Russia’s newly minted COVID-19 vaccine, Sputnik V. Lancet .20; 1128. published online Sept 4. https://doi.org/10.1016/S0140-6736(20)31866-3
Barbulescu A, Delcoigne B, Askling J, et al (2020)Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study. RMD Open6:e001201. https://doi.org/10.1136/rmdopen-2020-001201
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al (2020) Remdesivir for the treatment of covid-19—preliminary report. N Engl J Med 383(19):1813–1826. https://doi.org/10.1056/nejmoa2007764
Bertram S, Glowacka I, Muller MA, Lavender H, Gnirss K, Nehlmeier I, Niemeyer D, He Y, Simmons G, Drosten C et al (2011) Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol 85:13363–13372. https://doi.org/10.1128/jvi.05300-11
Bianchi M, Benvenuto D, Giovanetti M, Angeletti S, Cicozzi M, Pascarella S (2020) Sars-CoV-2 envelope and membrane proteins: structural differences linked to virus characteristics? Biomed Res Int 2020:1–6. https://doi.org/10.1155/2020/4389089
BioNTech (n.d.) mRNA therapeutics|BioNTech. https://biontech.de/how-we-translate/mrna-therapeutics. Accessed 22 Aug 2020
Blakney AK, McKay PF (2021) Next-generation COVID-19 vaccines: here come the proteins. Lancet. Vol 397 February 20, 2021. https://doi.org/10.1016/S0140-6736(21)00258-0
Bleyzac N, Goutelle S, Bourguignon L, Tod M (2020) Azithromycin for COVID-19: more than just an antimicrobial? Clin Drug Investig 40(8):683–686. https://doi.org/10.1007/s40261-020-00933-3
Bonomi L, Ghilardi L, Arnoldi E, Tondini CA, Bettini AC (2020) A rapid fatal evolution of coronavirus disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab. J Thorac Oncol 15(6):e83–e85. https://doi.org/10.1016/j.jtho.2020.03.021
Boriskin Y, Leneva I, Pecheur E-I, Polyak S (2008) Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15:997–1005
Cai X (2020) An insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis. Open Science Framework. https://doi.org/10.31219/osf.io/hw34x
Calisher C, Childs J, Field H, Holmes K, Schountz T (2006) Bats: important reservoir hosts of emerging viruses. Clin Microbiol Rev 19(3):531–545. https://doi.org/10.1128/CMR.00017-06
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res 178:104787. https://doi.org/10.1016/j.antiviral.2020.104787
Candido DS, Claro IM, de Jesus JG, et al. (2020). Evolution and epidemic spread of SARSCoV-2 in Brazil. Science. 369(6508):1255–60. https://doi.org/10.1126/science.abd2161
Cao B, Wang Y, Wen D et al (2020) A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382(19):1787–1799. https://doi.org/10.1056/NEJMoa2001282
Cavanagh D (1995) In: Siddell SG (ed) The Coronaviridae. Plenum, New York, pp 73–113
CDC. COVID-19: SARS-CoV-2 variant classifications and definitions. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
Chan JFW, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY (2015) Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:1904–1913. https://doi.org/10.1093/infdis/jiv392
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J et al (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395:514–523
Chandrashekar A et al (2020) SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369(6505):812–817. https://doi.org/10.1126/science.abc4776
Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39:529–539. https://doi.org/10.1007/s00281-017-0629-x
Charlton CL, Babady E, Ginocchio CC et al (2018) Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections. Clin Microbiol Rev 32(1):e00042–e00018. https://doi.org/10.1128/CMR.00042-18
Chen F, Chan KH, Jiang Y, Kao RYT, Lu HT, Fan KW, Cheng VCC, Tsui WHW, Hung IFN, Lee TSW, Guan Y, Peiris JSM, Yuen KY (2004) In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 31:69–75. https://doi.org/10.1016/j.jcv.2004.03.003
Chen PL, Zhang TX, Hu YH, Zhou CF, Wang SD (2005) A multicenter randomized controlled clinical study of recombinant human interferon-typeα1b in the treatment of viral pneumonia in children. Lin Chuang ErKe Za Zhi 23:244–245. (in Chinese)
Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X et al (2019) Management of cytokine release syndrome related to CAR-T cell therapy. Front Med 13:610–617. https://doi.org/10.1007/s11684-019-0714-8
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al (2020a) Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest 130:2620–2629. https://doi.org/10.1101/2020.02.16.20023903
Chen L, Liu H, Liu W, Liu J, Liu K, Shang J et al (2020b) Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. ZhonghuaJie He He Hu Xi Za Zhi 43:203–208. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0005
Chen N, Zhou M, Dong X et al (2020c) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513. https://doi.org/10.1016/S0140-6736(20)30211-7
Chen T, Wu D, Chen H et al (2020d) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368:m1091
Chhaiya SB, Mehta DS, Kataria BC (2012) Ivermecin: pharmacology and therapeutic applications. Int J Basic Clin Pharmacol 1:132–139
Chung MP, Park MS et al (2020) Safety and efficacy of pirfenidone in advanced idiopathic pulmonary fibrosis: a nationwide post-marketing surveillance study in Korean patients. Adv Ther 37(5):2303–2316. https://www.clinicaltrials.gov/ct2/show/NCT04412486 (as appeared on 03.09.2020)
COG-UK (2020) https://www.cogconsortium.uk/wp-content/uploads/2020/07/25th-June-2020-Report-COVID-19-Genomics-UK-COG-UK-Consortium.pdf (accessed on 12th April, 2021)
Corbett KS et al (2020) SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586(7830):567–571. https://doi.org/10.1038/s41586-020-2622-0
Costanzo L, Palumbo FP, Ardita G, Antignani PL, Arosio E, Failla G (2020) Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. J Vasc Surg Venous Lymphat Disord 8(5):711–716
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E (2020) The spike glycoprotein of the new coronavirus 2019- nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 176:104742
D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L (2020) Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management. Clin Gastroenterol Hepatol 18(8):1663–1672. https://doi.org/10.1016/j.cgh.2020.04.001
Daruich A et al (2020) Unilateral conjunctivitis as first presentation of coronavirus disease 2019 (COVID-19): a telemedicine diagnosis. J Fr Ophtalmol 43(5):e167–e168. https://doi.org/10.1016/j.jfo.2020.04.001
Davies NG, Barnard RC, Jarvis CI et al. (2020) Estimated Transmissibility and Severity of Novel SARS-CoV-2 Variant of Concern 202012/01 in England. medRxiv 2020
Deng G, Yin M, Chen X, Zeng F (2020) Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care 24:179
Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 14:58–60. https://doi.org/10.5582/ddt.2020.01012
Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8:62–73
Drosten C, Günther S, Preiser W, Van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RAM et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967–1976. https://doi.org/10.1056/NEJMoa030747
Duan K et al (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 117(17):9490–9496. https://doi.org/10.1073/pnas.2004168117
Ekdahl KN, Nilsson B (1995) Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b. J Immunol 154:6502–6510
Eriksson B, Helgstrand E, Johansson NG et al (1977) Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 11:946–951
Fears AC, Klimstra WB, Duprex P, Weaver SC, Plante JA, Aguilar PV et al (2020) Persistence of severe acute respiratory syndrome coronavirus 2 in aerosol suspensions. Emerg Infect Dis 26(9):2168–2171. https://doi.org/10.3201/eid2609.201806
Ferluga J, Kishore U, Sim RB (2014) A potential anti-coagulant role of complement factor H. Mol Immunol 59(2):188–193. https://doi.org/10.1016/j.molimm.2014.02.012
Ferrara F, Granata G, Pelliccia C et al (2020) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2. Eur J Clin Pharmacol 76(11):1615–1618
Flanagan KL, Fink AL, Plebanski M, Klein SL (2017) Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol 33:577–599
Folegatti PM (2020) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396(10249):467–478. https://doi.org/10.1016/S0140-6736(20)31604-4
Forgie S, Marrie TJ (2009) Healthcare-associated atypical pneumonia. Semin Respir Crit Care Med 30(1):67–85. https://doi.org/10.1055/s-0028-1119811
Funk CJ. Wang J. Ito Y. Travanty EA et al (2012) Infection of human alveolar macrophages by human coronavirus strain 229E. J Gen Virol. 93(Pt 3): 494–503.
Furuta Y, Gowen BB, Takahashi K et al (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446–454
Galloway SE. Paul P. MacCannell DR, et al (2021) Emergence of SARS-CoV-2 B.1.1.7 Lineage-United States, December 29,2020. MMWR Morb Mortal Wkly Rep. 70:95-99. https://doi.org/10.15585/mmwr.mm7003e2
Gao H, Zhang LL, Qin C, Duan ZJ, Tu XM, Yu ZA et al (2005) Experimental study on the prevention and treatment of SARS-CoV infection in rhesus monkeys with recombinant human interferon 2b nasal spray. Chin J Exp Clin Virol 19:207–211. (in Chinese)
Gao Q et al (2020a) Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369:77–81
Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H, Dong Q, Zhang Z, Wang Z, Hu Y, et al (2020b) Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv. 2020.03.29.20041962. https://doi.org/10.1101/2020.03.29.20041962
Gao Y, Li T, Han M, Li X, Wu D, Xu Y et al (2020c) Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 92:791–796. https://doi.org/10.1002/jmv.25770
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al (2020d) Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science https://doi.org/10.1126/science.abc1932
George PM, Wells AU, Jenkins RG (2020) Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 8(8):807–815. https://doi.org/10.1016/s2213-2600(20)30225-3
Ghebrehiwet B, Silverberg M, Kaplan AP (1981) Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153:665–676. [PubMed: 7252410]
Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP (1983) Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 71:1450–1456. [PubMed: 6304147]
Ghinai I et al (2020) First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet 395:1137–1144. https://doi.org/10.1016/S0140-6736(20)30607-3
Gómez CE, Perdiguero B, Esteban M (2021) Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines, 9, 243. https://doi.org/10.3390/vaccines9030243
Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Gotte M (2020) Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295(20):6785–6797. https://doi.org/10.1074/jbc.RA120.013679
Graci JD, Cameron CE (2006) Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16(1):37–48
Gralinski LE, Menachery VD (2020) Return of the coronavirus: 2019-nCoV. Viruses 12:135. (in English). https://doi.org/10.3390/v12020135
Grein J, Ohmagari N, Shin D, Diaz G (2020) Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med 382(25):e101. https://doi.org/10.1056/NEJMoa2007016
Grifoni A et al (2020) Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181:1489–1501
Guan W, Ni Z, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V et al (2020) Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2(8):e474–e484. https://doi.org/10.1016/S2665-9913(20)30173-9
Gulla KC, Gupta K, Krarup A, Gal P, Schwaeble WJ, Sim RB, O’Connor CD, Hajela K (2010) Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 129:482–495
Hachim A, Kavian N, Cohen CA et al (2020) ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nat Immunol 21(10):1293–1301. https://doi.org/10.1038/s41590-020-0773-7
Hack CE, Nuijens JH, Felt-Bersma RJ, Schreuder WO, Eerenberg-Belmer AJ, Paardekooper J, Bronsveld W, Thijs LG (1989) Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 86:20–26
Hajishengallis G, Lambris JD (2010) Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 31:154–163
Hamad OA, Nilsson PH, Lasaosa M, Ricklin D, Lambris JD, Nilsson B, Ekdahl KN (2010) Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One 5:e12889. [PubMed: 20886107]
Hao X et al (2020) Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. Nature 584(7821):420–424. https://doi.org/10.1038/s41586-020-2554-8
Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J (2005) C5a negatively regulates toll like receptor 4-induced immune responses. Immunity 22:415–426
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526–1529
Ho JC, Chan KN, Hu WH et al (2001) The effect of aging on nasal mucocilliary clearance, beat frequency, and ultrastructure of respiratory cilia. Am J Respir Crit Care Med 163:983–988
Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:1–10. https://doi.org/10.1016/j.cell.2020.02.052
Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, et al 2020 Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv. https://doi.org/10.1101/2020.06.22.20137273, 06.22.20137273
Hsieh MH, Beirag N, Murugaiah V, Chou Y-C, Kuo W-S, Kao H-F, Madan T, Kishore U, Wang J-Y. 2021. A recombinant fragment of Human Surfactant Protein D binds SARS-CoV-2 Spike protein and acts as an entry inhibitor of Pseudotyped viral particles. Frontiers in Immunology, 12:641360. https://doi.org/10.3389/fimmu.2021.641360
https://clinicaltrials.gov/ct2/show/NCT04315948. 22.03.2020
Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Hung IF, Lung K, Tso EY, Liu R, Chung TW, Chu MY et al (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395(10238):1695–1704. https://doi.org/10.1016/s0140-6736(20)31042-4
Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, Liu S, Yang J-K (2020) Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 8:152. https://doi.org/10.3389/fpubh.2020.00152
Juno JA, Tan H-X, Lee WS, Reynaldi A, Kelly HG, Wragg K et al (2020) Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med 26(9):1428–1434. https://doi.org/10.1038/s41591-020-0995-0
Kalaiyarasu S, Kumar M, Senthil Kumar D, Bhatia S, Dash SK, Bhat S et al (2016) Highly pathogenic avian influenza H5N1 virus induces cytokine dysregulation with suppressed maturation of chicken monocyte-derived dendritic cells. Microbiol Immunol 60:687–693. https://doi.org/10.1111/1348-0421.12443
Kam Y, Kien F, Roberts A, Cheung Y, Lamirande E, Vogel L, Chu S, Tse J, Guarner J, Zaki S, Subbarao K, Peiris M, Nal B, Altmeyer R (2007) Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. Vaccine 25(4):729–740
Kam Y, Okumura Y, Kido H, Ng L, Bruzzone R, Altmeyer R (2009) Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. PLoS One 4(11):e7870
Kemp SA, Harvey WT, Datir RP, et al. (2021). Recurrent emergence and transmission of SARS-CoV-2 spike deletion ΔH69/V70. bioRxiv [Preprint posted online January 14, 2021]. https://www.biorxiv.org/content/10.1101/2020.12.14.422555v4
Kerslake R, Hall M, Randeva H, Spandidos D, Chatha K, Kyrou I, Karteris E (2020) Co-expression of peripheral olfactory receptors with SARS-CoV-2 infection mediators: potential implications beyond loss of smell as a COVID-19 symptom. Int J Mol Med 46(3):949–956. https://doi.org/10.3892/ijmm.2020.4646
Killerby ME, Biggs HM, Midgley CM, Gerber SI, Watson JT (2020) Middle East respiratory syndrome coronavirus transmission. Emerg Infect Dis 26:191–198. https://doi.org/10.3201/eid2602.190697
Kim D, Lee J, Yang J, Kim J, Kim V, Chang H (2020) The Architecture of SARS-CoV-2 Transcriptome. Cell, 181(4), pp.914-921.e10.
Kishore U, Sim RB (2012) Factor has a regulator ofthe classical pathway activation. Immunobiology 217:162–168
Klein SL (2012) Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays 34:1050–1059
Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16:626–638
Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147. https://doi.org/10.1016/j.thromres.2020.04.013
Krarup A, Wallis R, Presanis JS, Gal P, Sim RB (2007) Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2:e623
Krilov LR (2001) Respiratory syncytial Vrus: update on infection, treatment, and prevention. Curr Infect Dis Rep 3:242–246
Kristina K, Waldenstrom J, Tang K, Lagging M (2020) Ribavirin: pharmacology, multiple modes of action and possible future perspectives. Future Virol 14(3):153–160. https://doi.org/10.2217/fvl-2018-0166
Kritas SK et al (2020) Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents 34(1):9–14. https://doi.org/10.23812/20-Editorial-Kritas
Kroon Campos R, Preciado-Llanes L, Azar S, Lopez-Camacho C, Reyes-Sandoval A, Rossi S (2019) A single and un-adjuvanted dose of a chimpanzee adenovirus-vectored vaccine against Chikungunya virus fully protects mice from lethal disease. Pathogens 8(4):231
Lan J, Ge J, Yu J et al (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581:215–220. https://doi.org/10.1038/s41586-020-2180-5
Lau SK, Woo PC, Li KS et al (2005) Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 102:14040–14045. https://doi.org/10.1073/pnas.0506735102
Le Berre A et al (2020) Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. Diagn Interv Imaging 101(5):321–322. https://doi.org/10.1016/j.diii.2020.04.003
Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M et al (2020) SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584(7821):457–462
Lei J, Li J, Li X, Qi X (2020) CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 295(1):18. https://doi.org/10.1148/radiol.2020200236
Leth-Larsen R. Zhong F. Chow VTK. Holmskov U. Lu J (2007). The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages.Immunobiology. 212(3): 201–211
Li F, Li W, Farzan M, Harrison SC (2005) Structural biology: structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309:1864–1868. https://doi.org/10.1126/science.1116480
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al (2020a) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199–1207. https://doi.org/10.1056/NEJMoa2001316
Li L et al (2020b) Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA 324:1–11
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y et al (2020c) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146(1):110–118. https://doi.org/10.1016/j.jaci.2020.04.006
Liang W et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21:335–337
Ling Z, Xu X, Gan Q, Zhang L, Luo L, Tang X, Liu J (2020) Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings. Eur J Radiol 126:108956. https://doi.org/10.1016/j.ejrad.2020.108956
Liu P, Shi L, Zhang W et al (2017) Prevalence and genetic diversity analysis of human coronaviruses among cross-border children. Virol J 14(1):230. https://doi.org/10.1186/s12985-017-0896-0
Liu BM, Yang QQ, Zhao LY, Xie W, Si XY (2020a) Epidemiological characteristics of COVID-19 patients in convalescence period. Epidemiol Infect 148:e108. https://doi.org/10.1017/s0950268820001181
Liu J, Liu Y, Xiang P et al (2020b) Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 18:206. https://doi.org/10.1186/s12967-020-02374-0
Logunov DY, Dolzhikova IV, Zubkova OV, etal (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet; 396: 887–97 Published Online September 4, 2020 https://doi.org/10.1016/S0140-6736(20)31866-3
Logunov DY, Dolzhikova IV, Shcheblyakov AV. et al. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397:10275 P671-681. https://doi.org/10.1016/S0140-6736(21)00234-8
Lokugamage KG, Schindewolf C, Menachery VD, 2020. SARS-CoV-2 sensitive to type I interferon pretreatment. BioRxiv. https://doi.org/10.1101/2020.03.07.982264
Long Q, Liu B, Deng H et al (2020a) Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26(6):845–848. https://doi.org/10.1038/s41591-020-0897-1
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ et al (2020b) Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26:1200–1204
Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EKY, Fish EN (2003) Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. J Am Med Assoc 290:3222–3228. https://doi.org/10.1001/jama.290.24.3222
Lu H (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 14(1):69–71. https://doi.org/10.5582/bst.2020.01020
Madan T, Biswas B, Varghese P, Subedi R, Pandit H, Idicula-Thomas S, et al (2021) A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples.Am J Respir Cell Mol Biol. 65 (1): 41–53. https://doi.org/10.1165/rcmb.2021-0005OC
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J et al (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007
Mallapaty S (2020) Will antibody tests for the coronavirus really change everything? Nature 580:571–572
Martines RB et al (2020) Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg Infect Dis 26(9):2005–2015
Mason RJ (2020) Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 55:2000607. https://doi.org/10.1183/13993003.00607-2020
Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC et al (2020) The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol 215:108450. https://doi.org/10.1016/j.clim.2020.108450
Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F (2010) Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 84:12658–12664. https://doi.org/10.1128/JVI.01542-10
Mazumder A, Arora M, Bharadiya V et al (2020) SARS-CoV-2 epidemic in India: epidemiological features and in silico analysis of the effect of interventions [version 1; peer review: awaiting peer review]. F1000 Res 9:315. https://doi.org/10.12688/f1000research.23496.1
McCarthy KR, Rennick LJ, Namnulli S, et al. (2020) Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. bioRxiv [Preprint posted online November 19, 2020]. https://www.biorxiv.org/content/10.1101/2020.11.19.389916v1
Mehta V et al (2020) Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 10(7):935–941. https://doi.org/10.1158/2159-8290.CD20-0516
Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Janne OA (2010) Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol 317:14–24
Miller JP, Kigwana LJ, Streeter DG et al (1997) The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci 284:211–229
Mizumoto K, Kagaya K, Zarebski A, Chowell G (2020) Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 25(10):2000180. https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000180
Monto AS, DeJonge P, Callear AP et al (2020) Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. J Infect Dis 222(1):9–16. https://doi.org/10.1093/infdis/jiaa161
Montopoli M et al (2020) Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n = 4532). Ann Oncol 31(8):1040–1045. https://doi.org/10.1016/j.annonc.2020.04.479
Moreno-Eutimio MA, Lopez-Macias C, Pastelin-Palacios R (2020) Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect 22(4-5):226–229. https://doi.org/10.1016/j.micinf.2020.04.009
Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J (2005) Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 326:905–908. https://doi.org/10.1016/j.bbrc.2004.11.128
Muller F, Mutch NJ, Schenk WA, Smith SA, Esteri L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139:1143–1156
National Health Commission of People’s Republic of China (2020) Diagnosis and treatment of pneumonia caused by novel coronavirus (trial version 4)
National Institute for Health Research (2020). First drug to reduce mortality in hospitalised patients with respiratory complications of COVID-19 found. https://www.nihr.ac.uk/news/first-drug-to-reduce-mortality-in-hospitalised-patients-withrespiratory-complications-of-covid-19-found/25061. Accessed 23 June 2020
Navarro-Millan I, Sattui S, Lakhanpal A, Zisa D, Siegel C, Crow M (2020) Use of Anakinra to prevent mechanical ventilation in severe COVID-19: a case series. Arthritis Rheumatol 72(12):1990–1997. https://doi.org/10.1002/art.41422
Neuman BW, Kiss G, Kunding AH et al (2011) A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol 174(1):11–22. https://doi.org/10.1016/j.jsb.2010.11.021
Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H et al (2020) Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52(6):971–977.e3. https://doi.org/10.1016/j.immuni.2020.04.023
Nishiura H et al (2020) Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 94:154–155. https://doi.org/10.1016/j.ijid.2020.03.020
Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir Res 105:17–21. https://doi.org/10.1016/j.antiviral.2014.02.014
Oikonomopoulou K (2012) Interactions between coagulation and complement—their role in inflammation. Katerina SeminImmunopathol 34(1):151–165. https://doi.org/10.1007/s00281-011-0280-x
Oliver CM, Campbell M, Dulan O et al (2020) Appearance and management of COVID-19 laryngo-tracheitis: two case reports [version 1; peer review: awaiting peer review]. F1000 Res 9:310. https://doi.org/10.12688/f1000research.23204.1
Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, Almakhlafi GA, Albarrak MM, Memish ZA, Albarrak AM (2014) Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14:1090–1095. https://doi.org/10.1016/S1473-3099(14)70920-X
Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323(18):1775–1776. https://doi.org/10.1001/jama.2020.4683
Pan Y, Zhang D, Yang P, Poon LLM, Wang Q (2020a) Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 20(4):411–412. https://doi.org/10.1016/s1473-3099(20)30113-4
Pan X, Chen D, Xia Y, Wu X, Li T, Ou X et al (2020b) Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis 20(4):410–411. https://doi.org/10.1016/s1473-3099(20)30114-6
Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V (2020) Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 18:1738–1742
Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN (2020) Prolonged infectivity of SARS-CoV-2 in fomites. Emerg Infect Dis 26(9):2256–2257. https://doi.org/10.3201/eid2609.201788
Pharmaceuticals I (2020) Innovations C for EP. Safety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers. https://clinicaltrials.gov/ct2/show/record/NCT04336410. Accessed 18 May 2020
Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal Of Medicine, 383(27), 2603-2615. https://doi.org/10.1056/nejmoa2034577
Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England—technical briefing 17. London, United Kingdom: Public Health England; 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997418/Variants_of_Concern_VOC_Technical_Briefing_17.pdf
Qi F, Qian S, Zhang S, Zhang Z (2020) Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun 526(1):135–140. https://doi.org/10.1016/j.bbrc.2020.03.044
Rambaldi A, Gritti G, Micò MC, Frigeni M, Borleri G et al (2020) Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor Narsoplimab. Immunobiology 225(6):152001. https://doi.org/10.1016/j.imbio.2020.152001
Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383:1503–1516
Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M et al (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 18(7):1747–1751. https://doi.org/10.1111/jth.14854
Ren LL, Wang YM, Wu ZQ et al (2020) Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J 133(9):1015–1024. https://doi.org/10.1097/CM9.0000000000000722
Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C (2012) In vivo roles of factor XII. Blood 120:4296–4303
Resende PC, Bezerra JF, de Vasconcelos RHT et al. (2021) Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil. 10 January. https://virological.org/t/spike-e484k-mutation-in-the-firstsars-cov-2-reinfection-case-confirmed-in-brazil-2020/584
Richmond P, Hatchuel L, Dong M, et al (2021) Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 397: 682–94 https://doi.org/10.1016/S0140-6736(21)00241-5
Rittirsch D, Flierl MA, Ward PA (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8:776–787
Roboz, J., (1977) The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci 284:211–229
Rocha CD, Caetano BC, Machado AV, Bruna-Romero O (2004) Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7:83–94
Rogers TF et al (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369(6506):956–963. https://doi.org/10.1126/science.abc7520
Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C et al (2020) Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 382(10):970–971. https://www.nejm.org/doi/pdf/10.1056/NEJMc2001468?articleTools=true
Rottier PJM (1995) In: Siddell SG (ed) The Coronaviridae. Plenum, New York, pp 115–139
Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46:846–848. https://doi.org/10.1007/s00134-020-06028-z
Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F et al (2020) Type 1 interferons as a potential treatment against COVID-19. Antivir Res 178:104791. https://doi.org/10.1016/j.antiviral.2020.104791
Samuel C (2001) Antiviral actions of interferons. Clin Microbiol Rev 14(4):778–809
Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E (2016) Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest 149:1294–1301
Sekine T, Perez-Potti A, Rivera-Ballesteros O (2020) Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183(1):158–168.e14. https://doi.org/10.1016/j.cell.2020.08.017
Sha J, Kirtley ML, Klages C, Erova TE, Telepnev M et al (2016) A replication-defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates. Clin Vaccine Immunol 23:586–600. https://doi.org/10.1128/CVI.00150-16
Shang YX, Huang Y, Liu EM, Chen Q, Cao L, Lu M et al (2014) A multicenter study on the treatment of acute bronchiolitis by nebulized human recombinant human interferon-alpha 1b. Zhongguo Shi Yong ErKe Za Zhi 29:840–844. (in Chinese)
Shang J, Ye G, Shi K et al (2020a) Structural basis of receptor recognition by SARS-CoV-2. Nature 581:221–224. https://doi.org/10.1038/s41586-020-2179-y
Shang J, Wana Y, Luoa C, Yea G, Genga Q, Auerbacha A, Lia F (2020b) Cell entry mechanisms of SARS-CoV-2. PNAS 117(21):11727–11734. https://www.pnas.org/cgi/doi/10.1073/pnas.2003138117
Sheahan TP, Sims AC, Leist SR et al (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222
Shen KL, Yang YH (2020) Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr 16(3):219–221. https://doi.org/10.1007/s12519-020-00344-6
Shen KL, Shang YX, Zhang GC, Xu BP, Fu Z, Cao L et al (2018) Rational use of interferon alpha in pediatrical clinical practice: experts’ consensus statement. Zhonghua Shi Yong ErKe Za Zhi 33:1301–1308. (in Chinese)
Shen Q, Xiao X, Aierken A, Liao M, Hua J (2020) The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS-CoV-2 infection. J Cell Mol Med 24(16):9472–9477. https://doi.org/10.31219/osf.io/fs5hd
Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. PharmacolTher 209:107512
Silva JC, Mariz HA, Rocha LF Jr, Oliveira PS, Dantas AT, Duarte AL et al (2013) Hydroxychloroquine decreases Th-17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo) 68:766–771
Skendros P et al (2020) Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 130(11):6151–6157. https://doi.org/10.1172/JCI141374
Song HD, Tu CC, Zhang GW, Wang SY et al (2005) Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A 102:2430–2435. https://doi.org/10.1073/pnas.0409608102
Sun D (2020) Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer additional benefit. AAPS J 22:77. https://doi.org/10.1208/s12248-020-00459-8
Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, Peng P, Liu X, Chen Z, Huang H, Zhang F, Luo W, Niu X, Hu P, Wang L, Peng H, Huang Z, Feng L, Li F, Zhang F, Li F, Zhong N, Chen L (2020a) Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbe Infect 9(1):940–948
Sun J, Zhu A, Li H, Zheng K, Zhuang Z, Chen Z et al (2020b) Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. Emerg Microbes Infect 9:991–993
Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen et al. (2020). SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med;26(5):681-687 doi:https://doi.org/10.1038/s41591-020-0868-6
Sutton D, Fuchs K, D'Alton M, Goffman D (2020) Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med 382:2163–2164. https://doi.org/10.1056/NEJMc2009316
Takahashi T, Ellingson MK, Wong P et al (2020) Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588(7837):315–320. https://doi.org/10.1038/s41586-020-2700-3
Tan LA, Yu B, Sim FCJ, Kishore U, Sim RB (2010) Complement activation by phospholipids: the interplay of factor H and C1q. Protein Cell 1:1033–1049
Taneja V (2018) Sex hormones determine immune response. Front Immunol 9:1931. https://doi.org/10.3389/fimmu.2018.01931
Tang N, Li D, Wang X, Sun Z (2020a) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844–847
Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S (2020b) Coronavirus membrane fusion mechanism offers as a potential target for antiviral development. Antiviral Res 178:104792. https://doi.org/10.1016/j.antiviral.2020.104792
Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10(4):616–629. https://doi.org/10.1016/j.ymthe.2004.07.013
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20(6):363–374. https://doi.org/10.1038/s41577-020-0311-8
To KK et al (2020) Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 20(5):565–574. https://doi.org/10.1016/S1473-3099(20)30196-1
Tong ZD et al (2020) Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China. Emerg Infect Dis 26:1052–1054. https://doi.org/10.3201/eid2605.200198
Tooze J, Tooze S, Warren G (1984) Replication of coronavirus MHV-A59 in sac-cells: determination of the first site of budding of progeny virions. Eur J Cell Biol 33:281–293. PMID: 6325194
Vaira LA, Salzano G, Deiana G, De Riu G (2020) Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope 130:1787. https://doi.org/10.1002/lary.28692
van der Hoek L, Sure K, Ihorst G et al (2005) Croup is associated with the novel coronavirus NL63. PLoS Med 2:e240. https://doi.org/10.1371/journal.pmed.0020240
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI et al (2020) Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 382(16):1564–1567
Van Voris LP, Newell PM (1993) Antivirals for the chemoprophylaxis and treatment of influenza. Semin Respir Infect 7:61–70
Varghese PM et al (2020) Host-pathogen interaction in COVID-19: potential therapeutics and vaccination strategies. Immunobiology 225(6):152008
Vasques Nonaka CK, Miranda Franco M, Gräf T, et al. (2021) Genomic Evidence of a Sars-CoV-2 Reinfection Case With E484K Spike Mutation in Brazil. https://www.preprints.org/manuscript/202101.0132/v1
Verdia-Baguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torress J, Anguilella VM, Enjuanes L (2012) Coronavirus E protein forms ion channes with functionally and structurally-involved membrane lipids. Virology 432:485–494
VillalaÃn J (2010) Membranotropic effects of Arbidol, a broad anti-viral molecule, on phospholipid model membranes. J Phys Chem B 114(25):8544–8554
Vincent MJ, Bergeron E, Benjannet S et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https://doi.org/10.1186/1743-422X-2-69S
Volz E, Hill V, McCrone JT, et al (2021) COG-UK Consortium. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 184:64–75.e11
Voysey M, Clemens SAC, Madhi SA, et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet; 397: 99–111
Walls AC et al (2020a) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–292
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020b) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–292.e6
Wang H, Zhang L (2020) Risk of COVID-19 for patients with cancer. Lancet Oncol 21:e181
Wang C, Horby PW, Hayden FG, Gao GF (2020a) A novel coronavirus outbreak of global health concern. Lancet 395(10223):470–473. https://doi.org/10.1016/S0140-6736(20)30185-9
Wang D, Hu B, Hu C et al (2020b) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069. https://doi.org/10.1001/jama.2020.1585
Wang H et al (2020c) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182(3):713–721.e9. https://doi.org/10.1016/j.cell.2020.06.008
Wang L, Gao Y-H, Lou L-L et al (2020d) The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J 55(4):2000398. https://doi.org/10.1183/13993003.00398-2020
Wang M, Cao R, Zhang L, Yang X et al (2020e) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitri. Cell Res 30(3):269–271. https://doi.org/10.1038/s41422-020-0282-0
Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L (2020f) Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis 221(11):1770–1774
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao G, Tan W, Yang X (2020g) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182(3):713–721.e9
Warren T, Jordan R, Lo M et al (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381–385. https://doi.org/10.1038/nature17180
Wei X et al (2020) Sex differences in severity and mortality among patients with COVID-19: evidence from pooled literature analysis and insights from integrated bioinformatic analysis. arxiv
Report of the WHO-China joint Mission on coronavirus disease 2019 (COVID-19) 16–24 February 2020. Geneva: World Health Organization; 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
WHO Coronavirus disease (COVID-19) Dashboard https://covid19.who.int/?gclid=Cj0KCQjwhb36BRCfARIsAKcXh6HCzQZUKFtQ-S7SfYgwOXj3Z4KeQ-L1rJnTjNMSb3EaQiUylzMSf_saAnrbEALw_wcB. 03.09.2020
WHO Report (2021a) Coronavirus disease (COVID-19) advice for the public: Mythbusters. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters#dexamethasone (as accessed on 14th April, 2021)
WHO Report (2021b) Coronavirus disease (COVID-19) advice for the public: Mythbusters.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice for public/mythbusters?gclid=EAIaIQobChMIpvm9j__97wIVkH4rCh3TlwU6EAAYASAAEgKlBvD_BwE#chloroquine (as accessed on 14th April, 2021)
WHO Report (2021c) The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know.HYPERLINK “https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-toknow?gclid=EAIaIQobChMI9rHG7LH%207wIVBqyWCh (accessed on 15th April, 2021)
Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C et al (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581:465–469
Woloshin S, Patel N, Kesselheim AS (2020) False negative tests for SARSCoV-2 infection—challenges and implications. N Engl J Med 383(6):e38
World Health Organization (2020) WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020 [Internet]. Geneva (Switzerland), World Health Organization. 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260–1263
Wu Z, McGoogan JM (2020) Characteristics of and important lesions from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Centre for Disease Control and Prevention. JAMA 323(13):1239–1242. PMID: 32091533. https://doi.org/10.1001/jama.2020.2648
Wu D, Tu C, Xin C, Xuan H et al (2005) Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates. J Virol 79:2620–2625. https://doi.org/10.1128/JVI.79.4.2620-2625.2005
Wu YP. Liu ZH, Wei R, Pan SD et al (2009) Elevated Plasma Surfactant Protein D (SP-D) levels and a direct correlation with Anti-Severe Acute Respiratory Syndrome Coronavirus-specific IgG antibody in SARS Patients. Scand J Immunol. 69(6):508-15. https://doi.org/10.1111/j.1365-3083.2009.02245.x
Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G et al (2020a) A new coronavirus associated with human respiratory disease in China. Nature 579:265–269
Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X et al (2020b) Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 5(5):434–435
Xia Y, Jin R, Zhao J, Li W, Shen H (2020) Risk of COVID-19 for patients with cancer. Lancet Oncol 21:e180
Xiang Z-Q, Gao GG, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HCJ (2002) Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76:2667–2675
Xiang P, Xu XM, Gao LL, Wang HZ, Xiong HF, Li RH, et al (2020) First case of 2019 novel coronavirus disease with encephalitis. ChinaXiv T202003.00015
Xu X, Han M, Li T, Sun W, Wang D et al (2020a) Effective treatment of severe COVID-19 patients with Tocilizumab. Proc Natl Acad Sci U S A 117:11970–11975. https://doi.org/10.1073/pnas.2005615117
Xu Z et al (2020b) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:420–422. https://doi.org/10.1016/S2213-2600(20)30076-X
Xu K et al (2020c) Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis 71(15):799–806. https://doi.org/10.1093/cid/ciaa351
Yang M (2020) Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN. https://doi.org/10.2139/ssrn.3527420
Yasmin H, Kishore U (2021) Biological Activities of SP-A and SP-D Against Extracellular and Intracellular Pathogens. The Collectin Protein Family and Its Multiple Biological Activities, 103–133. https://doi.org/10.1007/978-3-030-67048-1_5
Ye M, Ren Y, Lv T (2020) Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun 88:945–946
Younger JG, Bracho DO, Chung-Esaki HM, Lee M, Rana GK, Sen A, Jones AE (2010) Complement activation in emergency department patients with severe sepsis. Acad Emerg Med 17:353–359
Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A et al (2020) DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369(6505):806–811. https://doi.org/10.1126/science.abc6284
Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814–1820. https://doi.org/10.1056/NEJMoa1211721
Zhang L, Zhu F, Xie L, Wang C et al (2020a) Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 31(7):894–901. https://doi.org/10.1016/j.annonc.2020.03.296
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al (2020b) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38. https://doi.org/10.1056/nejmc2007575
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y et al (2020) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 71(16):2027–2034
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273
Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001017
Zhu F, Guan X, Hou L et al (2020a) Immunogenicity and safety of recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396(10249):479–488. https://doi.org/10.1016/S0140-6736(20)31605-6
Zhu F, Li Y, Guan X, Hou L, Wang W, Li, et al. (2020b) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395(10240):1845–1854. https://doi.org/10.1016/s0140-6736(20)31208-3
Zmora P, Hoffmann M, Kollmus H, Moldenhauer A, Danov O, Braun A, Winkler M, Schughart K, Pöhlmann S (2018) TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1. J Biol Chem 293(36):13863–13873
Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M et al (2020) Neutrophil extracellular traps in COVID-19. JCI Insight 5(11):e138999. https://doi.org/10.1172/jci.insight.138999
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yasmin, H., Saha, S., Butt, M.T., Modi, R.K., George, A.J.T., Kishore, U. (2021). SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. In: Kishore, U. (eds) Microbial Pathogenesis. Advances in Experimental Medicine and Biology, vol 1313. Springer, Cham. https://doi.org/10.1007/978-3-030-67452-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-67452-6_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-67451-9
Online ISBN: 978-3-030-67452-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)